AFROCAB calls for action to accelerate LEN
- info865664
- Jun 26
- 1 min read
On June 21, 2024, the Afrocab Treatment Access Partnership (AFROCAB) wrote to Gilead Sciences, an American biopharmaceutical company that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, calling for faster access to Lenacapavir for vulnerable populations, particularly adolescent girls and young women.
Below is the statement:
Comments